New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTBLUE, BLUE, BMRN, BMRN, CELG, CELG, CLDN, CLDN, MDGN, MDGN, QURE, QURE, SGMO, SGMO, AGTC, AGTC, ALGN, ALGNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer discusses gene therapy and highlights public and private companies involved in the field, as well as the large-cap pharma partnerships on an Analyst/Industry conference call. Relevant companies AGTC, ALGN, BLUE, BMRN, CELG, CLDN, MDGN, QURE and SGMO may be included on the Analyst/Industry conference call to be held on June 18 at 2 pm.
News For AGTC;ALGN;BLUE;BMRN;CELG;CLDN;MDGN;QURE;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
12:59 EDTBMRNOn The Fly: Midday Wrap
Subscribe for More Information
12:21 EDTBMRNBioMarin rises after agreeing to buy DMD drug maker Prosensa
Subscribe for More Information
09:48 EDTBMRNBioMarin price target raised to $96 from $85 at Piper Jaffray
Piper Jaffray raised its price target for BioMarin (BMRN) shares to $96 saying the acquisition of Prosensa (RNA), while introducing new risk, makes sense given its expertise in Orphan Drug approvals. Piper keeps an Overweight rating on BioMarin.
09:23 EDTBMRNOn The Fly: Pre-market Movers
Subscribe for More Information
09:20 EDTBMRNProsensa buyout not good for Sarepta, says Piper Jaffray
Piper Jaffray says it views the Prosensa (RNA) acquisition by BioMarin (BMRN) as bad for Sarepta (SRPT) since the company now has to compete with a "significantly more experienced and better funded orphan drug player." Piper adds that the takeover announced this morning has no impact on Sarepta's current drug filing process for its Duchenne muscular dystrophy drug eteplirsen. It keeps a Neutral rating on Sarepta with a $20 price target. The stock is trading up 9% in pre-market trading to $17.16 after BioMarin paid a healthy premium to acquire its peer Prosensa.
09:20 EDTBMRNBioMarin says Prosensa deal does not reflect deterioration of pipeline
Subscribe for More Information
08:12 EDTBMRNSarepta rises after DMD competitor acquired at significant premium
Shares of Sarepta Therapeutics (SRPT) are up 9.5% to $17.23 in early pre-market trading after rival drugmaker Prosensa (RNA) agreed to be acquired by BioMarin (BMRN). BioMarin has offered to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680M. In addition, two approximately $80M contingent milestones are payable for the approval of drisapersen in the U.S. and Europe. Drisapersen is Prosensa's lead exon-skipping drug candidate for treating Duchenne muscular dystrophy, or DMD. Sarepta is at work on eteplirsen, its own exon-skipping therapeutic candidate for the treatment of DMD. Prosensa closed trading Friday at $11.44 and are up about 65% to $18.90 in pre-market trading following the deal announcement.
06:44 EDTBMRNBioMarin to host conference call
Subscribe for More Information
06:02 EDTBMRNBioMarin agrees to purchase all shares of Prosensa for $17.75 per share
Subscribe for More Information
November 21, 2014
06:04 EDTCELGCelgene receives positive CHMP opinion for OTEZLA
Celgene announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, or PDE4, in two therapeutic indications, for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or, who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light, or PUVA; alone or in combination with Disease Modifying Antirheumatic Drugs, or DMARD, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
November 19, 2014
09:39 EDTCELGCelgene management to meet with ISI Group
Subscribe for More Information
07:08 EDTSGMOSangamo says study demonstrates in vivo reversal of Huntington's disease signs
Subscribe for More Information
November 18, 2014
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
November 17, 2014
11:49 EDTBLUE, SGMOPiper Jaffray healthcare analysts to hold an analyst/industry conference call
Subscribe for More Information
07:16 EDTCELG, BLUEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
09:19 EDTAGTCApplied Genetic price target raised to $34 from $25 at Roth Capital
Roth Capital increased its price target on Applied Genetic as the firm is encouraged by what it sees as the continued progress of the company's clinical program, and by the company's efforts to expand its pipeline. The firm expects the company to report important data catalysts in 2015 and reiterates a Buy rating.
07:30 EDTCLDN, BLUECredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link
07:02 EDTAGTCApplied Genetic price target raised to $28 from $24 at Cantor
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use